Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.
Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Cinefra M, D'Amico M, Mazzoni E, Marino A, Sponziello F, Morelli F, Lombardi L, Silvestris N, Cinieri S. Orlando L, et al. Among authors: morelli f. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S83-9. doi: 10.1517/14728222.2011.648925. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443171 Review.
Adjuvant colon cancer chemotherapy: where we are and where we'll go.
Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N, Orlando L, Tonini G, Colucci G, Maiello E. Lombardi L, et al. Among authors: morelli f. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S34-41. doi: 10.1016/S0305-7372(10)70018-9. Cancer Treat Rev. 2010. PMID: 21129608 Review.
Chemokine receptor CXCR4: role in gastrointestinal cancer.
Lombardi L, Tavano F, Morelli F, Latiano TP, Di Sebastiano P, Maiello E. Lombardi L, et al. Among authors: morelli f. Crit Rev Oncol Hematol. 2013 Dec;88(3):696-705. doi: 10.1016/j.critrevonc.2013.08.005. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2013. PMID: 24120239 Review.
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.
Caffo O, Facchini G, Biasco E, Ferraù F, Morelli F, Donini M, Buttigliero C, Calvani N, Guida A, Chiuri VE, Basso U, Mucciarini C, Conteduca V, Rossetti S, Veccia A, Maines F, Kinspergher S, De Giorgi U. Caffo O, et al. Among authors: morelli f. Future Oncol. 2019 Apr;15(10):1115-1123. doi: 10.2217/fon-2018-0715. Epub 2019 Mar 19. Future Oncol. 2019. PMID: 30887825
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.
Rizzo A, Mollica V, Merler S, Morelli F, Sorgentoni G, Oderda M, Santoni M, Massari F. Rizzo A, et al. Among authors: morelli f. Expert Opin Drug Metab Toxicol. 2022 Mar;18(3):235-240. doi: 10.1080/17425255.2022.2072727. Epub 2022 May 5. Expert Opin Drug Metab Toxicol. 2022. PMID: 35485878
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A. Procopio G, et al. Among authors: morelli f. Future Oncol. 2014 Aug;10(10):1741-50. doi: 10.2217/fon.14.48. Epub 2014 Mar 18. Future Oncol. 2014. PMID: 24641206 Free article.
323 results